Semaglutide CAS 910463-68-2

Product Description:

Product Name: Semaglutide CAS NO: 910463-68-2

Synonyms:

Sermaglutide；

Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.0%

Long term Storage:-20 ± 5℃

We can provide GMP/DMF file support for this product, as well as other different standards to meet your different needs.

We can also provide the fillers used in the production process of semaglutide synchronously:

SP FOCUROSE FF

DEAE FOCUROSE FF

Silica C8

Somalutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogue developed by Novonordisk, Denmark. Semaglutide is a long-acting dosage form based on the basic structure of liraglutide, which is better for the treatment of type 2 diabetes mellitus. Novo NorNord has completed six PChemicalbookhaseIIIa studies and has filed a new drug registration application with the U.S. Food and Drug Administration (FDA) on December 5, 2016 for somalutide once a week. An application for marketing authorisation (MAA) has also been submitted to the European Medicines Agency (EMA). Somalutide, on the other hand, is currently in Phase III clinical use in a once-daily oral formulation.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.